I have to admit that I expected much more out of the stock price by now. Successful product launch after final DEA classification should have moved this stock up much more. Illustrates an extreme skepticism from the market, possible after the VVUS flop out of the gate, or possibly a powerful short position resisting any upward movement.
Hopefully it will finally move up substantially on strong script numbers.
Agree with Sharonconi below. WS continues to make incorrect assumptions, and IMHO being contrarian to them is a winner with ARNA. Their mistake? Physicians view Qsymia as a dangerous drug, a potential litigation nightmare, and something they want to use only if they have to. This is why Q's sales are so disappointing, among a dozen reasons. One cannot heuristcially extrapolate this to Belviq.
On the other hand, physicians view Belviq as new, novel, safe, and now proven more effective (see ADA data from last weekend presented in Chicago to physicians) than Q. Not realizing this early enough will be financial disaster for the shorts.